{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:02:03Z","timestamp":1785589323040,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.schres.2023.10.025","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T21:07:49Z","timestamp":1700341669000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-4614","authenticated-orcid":false,"given":"Trino","family":"Baptista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5910-8575","authenticated-orcid":false,"given":"Mariano","family":"Motuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-3342","authenticated-orcid":false,"given":"Ana","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7760-8987","authenticated-orcid":false,"given":"Alirio","family":"Perez Lo Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-2233","authenticated-orcid":false,"given":"Alberto","family":"Fernandez-Arana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3074-7637","authenticated-orcid":false,"given":"Ismael","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-6125","authenticated-orcid":false,"given":"Albis","family":"Pabon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3383-8384","authenticated-orcid":false,"given":"Juan Genaro Ayala","family":"Yepez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0784-3424","authenticated-orcid":false,"given":"Gabriel de Jesus","family":"Alejo Galarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8510-0102","authenticated-orcid":false,"given":"Nuria Monserrat","family":"Rivera Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-7511","authenticated-orcid":false,"given":"Helio","family":"Elkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-4435","authenticated-orcid":false,"given":"Emilio J.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-905X","authenticated-orcid":false,"given":"Carlos","family":"De Las Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.10.025_bb0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1590\/1516-4446-2018-0177","article-title":"Brazilian guidelines for the management of psychomotor agitation. Part 2. Pharmacological approach","volume":"41","author":"Baldacara","year":"2019","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0010","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/1516-4446-2014-1402","article-title":"A fatal case of ischemic colitis during clozapine administration","volume":"36","author":"Baptista","year":"2014","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.schres.2023.10.025_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2015.05.025","article-title":"Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics","volume":"166","author":"Baptista","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.025_bb0020","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/0004867415585584","article-title":"Heterogeneity of clozapine-associated myocarditis: an opportunity for novel preventing strategies","volume":"49","author":"Baptista","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0025","first-page":"352","article-title":"Clozapine-induced myocarditis in observational cross-sectional and follow-up evaluations: comparison with other antipsychotics in naturalistic settings","volume":"57","author":"Baptista","year":"2016","journal-title":"Investig. Clin."},{"key":"10.1016\/j.schres.2023.10.025_bb0030","article-title":"Clozapine safety monitoring and related research in psychiatry and neurology in South America: a scoping review","volume":"2023","author":"Baptista","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.025_bb0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/000486749202600212","article-title":"Looking beyond the 1:10,000 ratio of psychiatrists to population","volume":"26","author":"Burvill","year":"1992","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0034-7450(14)60113-X","article-title":"Miocarditis por clozapina: reporte de caso y revisi\u00f3n de tema","volume":"40","author":"Casta\u00f1eda Ram\u00edrez","year":"2011","journal-title":"Rev. Colomb. Psiquiatr."},{"key":"10.1016\/j.schres.2023.10.025_bb0045","first-page":"49","article-title":"Consenso argentino sobre diagn\u00f3stico y tratamiento de la esquizofrenia resistente al tratamiento [Argentine consensus on the diagnosis and therapeutics of treatment resistant schizophrenia]","volume":"154","author":"Corrales","year":"2021","journal-title":"Vertex"},{"key":"10.1016\/j.schres.2023.10.025_bb0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2023.10.025_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.rcp.2015.05.002","article-title":"Gu\u00edas de pr\u00e1ctica cl\u00ednica en esquizofrenia: evaluaci\u00f3n mediante AGREE II","volume":"43","author":"de la Hoz Bradford","year":"2014","journal-title":"Rev. Colomb. Psiquiatr."},{"key":"10.1016\/j.schres.2023.10.025_bb0060","article-title":"Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia)","author":"De Las Cuevas","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.025_bb0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.24869\/psyd.2022.411","article-title":"Reflections on the complex history of the concept of clozapine-induced inflammation during titration","volume":"34","author":"de Leon","year":"2022","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2023.10.025_bb0070","article-title":"Using therapeutic drug monitoring to personalize clozapine dosing in Asians","volume":"12, 2","author":"de Leon","year":"2020","journal-title":"Asia Pac. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using 6 ancestry-based personalized dosing titrations, CRP and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0080","first-page":"363","article-title":"Promoting safer clozapine dosing in the Americas","volume":"44","author":"de Leon","year":"2022","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JCP.0000000000001678","article-title":"Escaping the long shadow cast by agranulocytosis: reflections on clozapine pharmacovigilance focused on the United Kingdom","volume":"43","author":"de Leon","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Supl. 4","key":"10.1016\/j.schres.2023.10.025_bb0090","first-page":"S1","article-title":"Tratamiento de la esquizofrenia en M\u00e9xico: recomendaciones de un panel de expertos","volume":"157","author":"Escamilla-Orozco","year":"2021","journal-title":"Gac. Med. Mex."},{"key":"10.1016\/j.schres.2023.10.025_bb0095","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40263-017-0448-6","article-title":"Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal \u2018slow gut\u2019 reactions, and comparison with international drug safety advice","volume":"31","author":"Every-Palmer","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2023.10.025_bb0100","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/biom11071030","article-title":"Clozapine: why is it so uniquely effective in the treatment of a range of neuropsychiatric disorders?","volume":"11","author":"Gammon","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.schres.2023.10.025_bb0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1590\/1516-4446-2021-1765","article-title":"Risk of neutropenia among clozapine users and non-users: results from 5,847 patients","volume":"44","author":"Goldani","year":"2022","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.10.025_bb0115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.025_bb0120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.schres.2023.10.025_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.10.025_bb0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.euroneuro.2022.12.011","article-title":"Prevention of suicide by clozapine in mental disorders: systematic review","volume":"69","author":"Masdrakis","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.10.025_bb0135","author":"Ministerio de Salud, Gobierno de Chile"},{"key":"10.1016\/j.schres.2023.10.025_bb0140","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41380-021-01435-0","article-title":"Minimum and optimal numbers of psychiatric beds: expert consensus using a Delphi process","volume":"27","author":"Mundt","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103192","article-title":"Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia","volume":"74","author":"Quek","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.schres.2023.10.025_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15691","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","author":"Reeves","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.10.025_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.09.002","article-title":"An expert review of clozapine in Eastern European countries: use, regulations and pharmacovigilance","author":"Sagud","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.025_bb0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0004867413502089","article-title":"Safety of long-term clozapine administration. Frequency of cardiomyopathy and hyponatraemia: two cross-sectional, naturalistic studies","volume":"48","author":"Serrano","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0165","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/MJT.0000000000000735","article-title":"Clozapine for treatment-refractory behavioral disturbance in dementia","volume":"25","author":"Teodorescu","year":"2018","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.schres.2023.10.025_bb0170","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland","volume":"9","author":"Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.10.025_bb0175","author":"Uppsala Monitoring Centre"},{"key":"10.1016\/j.schres.2023.10.025_bb0180","author":"World Health Organization"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:05:05Z","timestamp":1730527505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423003869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":36,"alternative-id":["S0920996423003869"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.025","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}